Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

HoldenMeown Jan. 16 at 7:04 PM

$INTS

0 · Reply

lamMBD Jan. 16 at 6:46 PM

$INTS Mark my words!! When this finally pops, it's gonna pop so hard!!! I haven't seen a setup like this in quite a while. Some major players are holding this down! My assessment, a MAJOR partnership to be announced soon, or the BUYOUT we are anticipating! Lastly, NEVER forget, market makers know what's coming before any of us retail!! MBD

0 · Reply

joel12365 Jan. 16 at 6:11 PM

$INTS going to be a good full of news and data hopefully but heres where we stand phase 3 sarcoma orphan drug half way phase 2 breast cancer massive market and amazing results already (maybe partnered) phase 2 breast cancer with merck and bristol myers 80 billion market valuation alot of drugs are coming off the market so theh need to up there efficiency by any percent thats where the delivery stands 2 cancer institutions supporting and helping with resuls too. hints at phase 3 breast cancer too this year this is almost 100% partnered if results continue

0 · Reply

MoneyClaw Jan. 16 at 5:47 PM

$INTS hope y’all save some powder. It’s about to get ugly!

1 · Reply

Dannyrotorpilot Jan. 16 at 3:45 PM

$INTS I’m not invested in it but VERO is a similar setup. They teamed up and today, off to the races they went.

1 · Reply

lamMBD Jan. 16 at 2:48 PM

$INTS Sicc of these .40's!!! This is when PATIENCE really kicks in!! This is when wealth is transferred from the impatient to the patient!! WE ARE SO CLOSE LONGS! MBD

0 · Reply

Birdie1975 Jan. 16 at 6:07 AM

$INTS I hope something happens soon with this stock i have 70k shares at an average price of $.61 a share. I bought 20k 1.00 per share and just bought 50k share yesterday at .42 cents to average down to $.61 I hope I made the right decision after doing research on this company. I truly believe that one day it will be very valuable. What are your thoughts? Am I crazy or am I making the right decision?

4 · Reply

IggieKooppa Jan. 15 at 10:35 PM

$INTS Wen ? 😴😴😴

2 · Reply

lamMBD Jan. 15 at 9:24 PM

$INTS IT'S COMING, I CAN FEEL IT!!! MBD

0 · Reply

Jimmyjabba Jan. 15 at 5:41 PM

$INTS let's hear some chatter in the outfield! Hey batta batta.. sawing battaaa. To the moon Alice!

0 · Reply

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Dec 11, 2025, 7:47 AM EST - 5 weeks ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 7:30 AM EST - 6 weeks ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 6 weeks ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Nov 6, 2025, 4:02 PM EST - 2 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 1:36 PM EDT - 2 months ago

Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript

Oct 31, 2025, 8:00 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Sep 10, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:47 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 5 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 8 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 11 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

$Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023$

Nov 2, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 7, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 5, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HoldenMeown Jan. 16 at 7:04 PM

$INTS

0 · Reply

lamMBD Jan. 16 at 6:46 PM

0 · Reply

joel12365 Jan. 16 at 6:11 PM

0 · Reply

MoneyClaw Jan. 16 at 5:47 PM

$INTS hope y’all save some powder. It’s about to get ugly!

1 · Reply

Dannyrotorpilot Jan. 16 at 3:45 PM

$INTS I’m not invested in it but VERO is a similar setup. They teamed up and today, off to the races they went.

1 · Reply

lamMBD Jan. 16 at 2:48 PM

$INTS Sicc of these .40's!!! This is when PATIENCE really kicks in!! This is when wealth is transferred from the impatient to the patient!! WE ARE SO CLOSE LONGS! MBD

0 · Reply

Birdie1975 Jan. 16 at 6:07 AM

4 · Reply

IggieKooppa Jan. 15 at 10:35 PM

$INTS Wen ? 😴😴😴

2 · Reply

lamMBD Jan. 15 at 9:24 PM

$INTS IT'S COMING, I CAN FEEL IT!!! MBD

0 · Reply

Jimmyjabba Jan. 15 at 5:41 PM

$INTS let's hear some chatter in the outfield! Hey batta batta.. sawing battaaa. To the moon Alice!

0 · Reply

SBEEE Jan. 15 at 3:21 PM

$INTS

0 · Reply

SBEEE Jan. 15 at 3:20 PM

$INTS https://intensitytherapeutics.com/technology/

0 · Reply

DarkSonar Jan. 15 at 2:56 PM

$INTS People thinking because they have an extension or time to get compliant they won’t R/S. Don’t listen to the pumpers. Be careful

3 · Reply

Dannyrotorpilot Jan. 15 at 2:02 PM

$INTS fake news! They have an active extension until June. get outta here with that FUD.

0 · Reply

Zetergius Jan. 15 at 5:31 AM

$INTS @ Dark Sonar … there’s no filing for R/S, but good try!!

2 · Reply

DarkSonar Jan. 15 at 1:27 AM

$INTS Nice little chart!! Too bad they have active R/S. I’ll just wait till then!! 🔬

1 · Reply

EyeLikeTheStonk Jan. 14 at 11:09 PM

$INTS

1 · Reply

SBEEE Jan. 14 at 6:08 PM

$INTS Since they doing their trial in Switzerland that also make me think Roche could also be a wild card guess for buyout.

0 · Reply

lamMBD Jan. 14 at 4:53 PM

$INTS Anyday now longs. It's coming! MBD

0 · Reply

SBEEE Jan. 14 at 2:52 PM

$INTS My heart and mind both says if we are lucky Pfizer is going to buy us out soon. May be I am wrong let’s see.

1 · Reply

DarkSonar Jan. 14 at 2:41 PM

$INTS Loving the set up. Needs DD. Monitoring 🔬

0 · Reply

quito_yume Jan. 14 at 1:17 PM

$INTS

0 · Reply

Market Cap	25.11M
Revenue (ttm)	0.00
Net Income (ttm)	-16.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	759,700
Avg Vol	3,181,928
Day's Range	N/A - N/A
Shares Out	60.07M
Stochastic %K	41%
Beta	3.56
Analysts	Strong Sell
Price Target	$3.25